|
|
| | SRI 37892 Basic information |
| Product Name: | SRI 37892 | | Synonyms: | SRI 37892;Benzamide, 4-(1H-benzimidazol-1-yl)-N-[4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-2-thiazolyl]-;4-(1H-Benzo[d]imidazol-1-yl)-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)benzamide;SRI 37892, 10 mM in DMSO | | CAS: | 1030769-75-5 | | MF: | C26H19N5O2S | | MW: | 465.53 | | EINECS: | | | Product Categories: | | | Mol File: | 1030769-75-5.mol |  |
| | SRI 37892 Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | pka | 6.67±0.50(Predicted) | | form | Solid | | color | Light yellow to brown |
| | SRI 37892 Usage And Synthesis |
| Uses | SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC50=2μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents [1]. | | References | [1] Zhang W, et al. Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain. Oncotarget. 2017 Sep 6;8(53):91459-91470. DOI:10.18632/oncotarget.20665 |
| | SRI 37892 Preparation Products And Raw materials |
|